CG Oncology (CGON) Stock Price & Analysis

CGON$84.78+10.38 +13.95%
BiotechnologyGrowth Stock
Compare
Market cap$7.57BEnterprise value$5.99BRevenue (TTM)$6.23MMarket position—

Score

53
Neutral
Value
34
Quality
47
Growth
78

AI Analysis

Snapshot

CG Oncology is a growth-led story right now — Growth 78/100 is the pillar doing the heavy lifting (overall 53/100) in Biotechnology. Under the hood: revenue compounding ~240% annually over recent years.

Price History

Bullish (65+)Neutral (45–64)Bearish (<45)

Score Breakdown

Market percentile scores loading…

Value

34
PE Ratio (F)–
PEG Ratio–
Free Cashflow Yield %–
EV/EBITDA Ratio–
Discount vs All Time Peak–
Discount vs 1Y Peak–

Growth

78
Earnings Forecast–
Last 3M Earnings Growth %–
12M Revenue Growth %–
12M Earnings Growth %–
5 YR CAGR % Earnings–
Analyst Price Forecast–

Quality

47
FCF Margin %–
Net Debt / EBITDA–
Operating Margin %–
Operating Margin Growth %–
ROCE %–
Current Ratio–

Financial Summary

CG Oncology Inc. (CGON) last printed $84.78. Equity value is $7.57B. Trailing earnings multiple —. The revenue row is reported history. Targets and ratings are on the forecast page.

Financials

20212022202320242025
$10.36M$191,000.00$204,000.00$1.14M$4.04M

About

CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company’s product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC. It also develops cretostimogene monotherapy for intermediate-risk NMIBC following TURBT, which is in phase 3 PIVOT-006 clinical trials to assess the safety and efficacy of adjuvant cretostimogene; and cretostimogene monotherapy for high-risk NMIBC in phase 2 CORE-008 clinical trials to assess the safety and clinical outcomes of cretostimogene in treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC. The company was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. CG Oncology, Inc. was founded in 2010 and is headquartered in Irvine, California.

CG Oncology (CGON) Stock Price & Analysis

CGON price $84.78 +10.38 +13.95%

Ticker
CGON
Price
$84.78
Change
+10.38 +13.95%
Market cap
$7.57B
Forward P/E
23.60
Dividend yield
0.00%
Beta
0.24
Sector
Healthcare
Industry
Biotechnology
Stocklytics score
53
Value
34
Quality
47
Growth
78

Stocklytics score rationale: value 34, quality 47, growth 78.

AI Score 25. CG Oncology Inc. has a market cap of $6 billion but is facing significant financial challenges, with a net profit margin of -36.03% and a price-to-sales ratio of 963.69, indicating overvaluation relative to its revenue

Fair value

CGON fair value $45.41. Price $84.78. Price is 87% above fair value.

Fair value is an estimate of what one share is worth if future cash flows arrive as modeled. It is not a forecast of the share price.

Fair value blends a 10-year DCF and an earnings multiple: the average of the DCF value and an earnings value from next-twelve-months EPS times 28.5, a blend of the industry median and the stock's own 10-year median. How we calculate it →

Model uncertainty high for this stock

Compare CGON

Earnings

DateEPS actualEPS estimateRevenueRevenue estimate
2027-03-26—-0.72—922.34K
2027-02-26—-0.71—922.34K
2026-11-06-0.64-0.831.60M547.68K
2026-08-06-0.90-0.661.16M360.81K
2026-05-08-0.71-0.581.08M453.03K
2026-02-27-0.51-0.612.31M450.54K
2025-11-14-0.57-0.561.67M59.36K
2025-08-08-0.54-0.49—81.62K
2025-05-13-0.45-0.3952.00K118.17K
2025-03-28-0.48-0.41456.00K123.95K
2024-11-14—-0.42——
2024-08-08-0.28-0.42111.00K—
2024-05-09-0.36-0.35529.00K—
2024-03-26—-0.67——

Dividends

Yield 0.00%. Payout ratio 0.00%. Frequency —.

Safety score 37/100 · Watch. Payout ratio is 0% of earnings. Free-cash-flow coverage is not available, so this part stays neutral. No dividend history was found. There is no dividend yield.

Ex-dateDividendRecordPaymentFrequency
No data yet.

Insider trades

DateInsiderActionSharesPriceValue
2026-10-15Kalofonos IsabelBuy92.00K$61.865.69M
2026-10-15POST LEONARD ESell1.00K$0.60600
2026-10-15POST LEONARD EBuy1.00K$0.60600
2026-10-15POST LEONARD ESell500$61.6530.82K
2026-10-15POST LEONARD ESell500$62.4831.24K
2026-10-13Kalofonos IsabelOther0——
2026-09-15POST LEONARD ESell1.00K$0.60600
2026-09-15POST LEONARD EBuy1.00K$0.60600
2026-09-15POST LEONARD ESell1.00K$72.9872.98K
2026-08-14POST LEONARD ESell1.00K$0.60600
2026-08-14POST LEONARD EBuy1.00K$0.60600
2026-08-14POST LEONARD ESell1.00K$74.5474.54K
2026-07-15POST LEONARD ESell1.00K$0.60600
2026-07-15POST LEONARD EBuy1.00K$0.60600
2026-07-15POST LEONARD ESell1.00K$71.1771.17K
2026-07-10Mulay JamesBuy24.16K$26.63643.51K
2026-07-10Mulay JamesSell24.16K$26.63643.51K
2026-07-10Mulay JamesSell24.16K$75.161.82M
2026-06-25Liu Brian Guan-ChyunBuy371.08K$66.8724.81M
2026-06-24POST LEONARD ESell5.00K$0.603.00K
2026-06-24POST LEONARD EBuy5.00K$0.603.00K
2026-06-24POST LEONARD ESell5.00K$70.00350.00K
2026-06-22POST LEONARD ESell5.00K$0.603.00K
2026-06-22POST LEONARD EBuy5.00K$0.603.00K
2026-06-22POST LEONARD ESell5.00K$65.00325.00K
2026-06-15Mulay JamesSell1.31K$12.5916.49K
2026-06-15Mulay JamesBuy1.31K$12.5916.49K
2026-06-15Mulay JamesBuy654$3.722.43K
2026-06-15Mulay JamesSell654$3.722.43K
2026-06-15Mulay JamesSell1.31K$60.1278.76K
2026-06-04Liu Brian Guan-ChyunBuy9.35K$56.09524.67K
2026-06-04Tong Victor Edward JrBuy9.35K$56.09524.67K
2026-06-04Mulay JamesBuy9.35K$56.09524.67K
2026-06-04POST LEONARD ESell1.00K$0.60600
2026-06-04Rossi ChristinaBuy9.35K$56.09524.67K
2026-06-04POST LEONARD EBuy9.35K$56.09524.67K
2026-06-04POST LEONARD EBuy1.00K$0.60600
2026-06-04POST LEONARD ESell1.00K$54.5054.50K
2026-06-04Graf Susan EBuy9.35K$56.09524.67K
2026-04-17Mulay JamesBuy15.60K$36.63571.43K
2026-04-17Mulay JamesSell15.60K$36.63571.43K
2026-04-17Mulay JamesSell15.60K$73.011.14M
2026-04-15Bellete AmbawBuy107.51K$67.687.28M
2026-04-15Kasturi VijayBuy79.22K$67.685.36M
2026-04-15Patterson Joshua F.Buy45.27K$67.683.06M
2026-04-15DETORE JAMES M.Buy90.57K$67.686.13M
2026-04-15Kuan ArthurBuy271.60K$67.6818.38M
2026-03-16Mulay JamesSell1.31K$12.5916.49K
2026-03-16Mulay JamesBuy1.31K$12.5916.49K
2026-03-16Mulay JamesBuy654$3.722.43K
2026-03-16Mulay JamesSell654$3.722.43K
2026-03-16Mulay JamesSell1.31K$63.5083.19K
2026-03-12Kuan ArthurBuy64.61K$1.72111.13K
2026-03-12Kuan ArthurSell1.85K$60.15111.10K
2026-03-12Kuan ArthurSell64.61K$1.72111.13K
2026-03-04Kuan ArthurBuy102.87K$1.72176.94K
2026-03-04Kuan ArthurSell2.87K$61.61176.88K
2026-03-04Kuan ArthurSell102.87K$1.72176.94K
2026-01-09Mulay JamesBuy10.49K$12.59132.08K
2026-01-09Mulay JamesSell10.49K$12.59132.08K
2026-01-09Mulay JamesSell654$3.722.43K
2026-01-09Mulay JamesBuy654$3.722.43K
2026-01-09Mulay JamesSell654$44.1628.88K
2026-01-09Mulay JamesSell10.49K$52.99555.92K
2025-11-24Rossi ChristinaBuy20.89K$43.56909.92K
2025-11-24Rossi ChristinaOther0——
2025-11-17DETORE JAMES M.Other0——
2025-11-17POST LEONARD ESell1.00K$0.60600
2025-11-17POST LEONARD EBuy1.00K$0.60600
2025-11-17POST LEONARD ESell1.00K$41.4341.43K
2025-10-13POST LEONARD ESell1.00K$0.60600
2025-10-13POST LEONARD EBuy1.00K$0.60600
2025-10-13POST LEONARD ESell1.00K$43.2543.25K
2025-10-09Mulay JamesBuy5.90K$3.7221.96K
2025-10-09Mulay JamesSell5.90K$3.7221.96K
2025-10-09Mulay JamesSell5.90K$43.99259.67K
2025-09-30POST LEONARD ESell5.00K$0.603.00K
2025-09-30POST LEONARD EBuy5.00K$0.603.00K
2025-09-30POST LEONARD ESell5.00K$40.09200.45K
2025-09-29Mulay JamesBuy12.76K$1.8223.21K
2025-09-29Mulay JamesSell12.76K$1.8223.21K
2025-09-29Mulay JamesSell12.76K$39.19499.87K
2025-09-19Mulay JamesSell3.57K$1.826.50K
2025-09-19Mulay JamesBuy3.57K$1.826.50K
2025-09-19Mulay JamesSell3.57K$38.99139.35K
2025-09-18Mulay JamesBuy19.11K$1.8234.78K
2025-09-18Mulay JamesSell19.11K$1.8234.78K
2025-09-18Mulay JamesSell19.11K$39.01745.56K
2025-09-15POST LEONARD ESell1.00K$0.60600
2025-09-15POST LEONARD EBuy1.00K$0.60600
2025-09-15POST LEONARD ESell1.00K$35.1035.10K
2025-09-11Liu Brian Guan-ChyunBuy1.52M$33.0050.00M
2025-09-05Mulay JamesBuy27.02K$0.6016.21K
2025-09-05Mulay JamesSell12.34K$30.47376.06K
2025-09-05Mulay JamesSell4.09K$31.42128.66K
2025-09-05Mulay JamesSell7.46K$32.64243.66K
2025-09-05Mulay JamesSell27.02K$0.6016.21K
2025-09-05Mulay JamesSell3.11K$33.22103.41K
2025-09-03Song Hong FangSell69.69K$27.601.92M
2025-09-03Song Hong FangSell30.11K$28.24850.17K

Institutional holders

Latest filed quarter: Q3 2026.

Institutions holding: 169, holders -79 vs prior quarter. Ownership 49.69%.

HolderSharesChangeChange %Value
DECHENG CAPITAL LLC6.37M00.00%451.69M
BLACKROCK, INC.6.35M91.05K+1.46%449.96M
FMR LLC4.59M432.97K+10.40%325.70M
VANGUARD CAPITAL MANAGEMENT LLC3.57M257.24K+7.76%253.36M
VANGUARD PORTFOLIO MANAGEMENT LLC3.52M50.42K+1.46%249.22M
STATE STREET CORP3.23M-203.71K-5.93%229.25M
GEODE CAPITAL MANAGEMENT, LLC2.23M72.28K+3.36%157.80M
MORGAN STANLEY1.50M322.20K+27.37%106.29M
FRANKLIN TEMPLETON INC1.03M-281.83K-21.47%69.81M
HOOD RIVER CAPITAL MANAGEMENT LLC883.87K883.87KNew62.66M
JEFFERIES FINANCIAL GROUP INC.835.34K65.39K+8.49%59.22M
UBS GROUP AG737.89K-239.80K-24.53%52.31M
AMERICAN CENTURY COMPANIES INC730.54K4.38K+0.60%51.79M
CLEARBRIDGE INVESTMENTS, LLC613.05K-122.68K-16.68%43.46M
VANGUARD FIDUCIARY TRUST CO551.62K13.33K+2.48%39.10M
BNP PARIBAS FINANCIAL MARKETS523.16K523.16KNew37.09M
FISHER ASSET MANAGEMENT, LLC476.92K19.94K+4.36%33.81M
LORD, ABBETT & CO. LLC470.80K470.80KNew33.38M
WOODLINE PARTNERS LP415.21K-77.68K-15.76%29.43M
CANDRIAM S.C.A.375.36K-93.81K-19.99%26.71M
JPMORGAN CHASE & CO373.16K-44.57K-10.67%26.54M
EVENTIDE ASSET MANAGEMENT, LLC370.33K370.33KNew26.25M
DIMENSIONAL FUND ADVISORS LP349.37K-84.51K-19.48%24.77M
FEDERATED HERMES, INC.334.45K334.45KNew23.71M
ENSIGN PEAK ADVISORS, INC296.90K-83.65K-21.98%21.05M

Insights · Forecast · Financials · Learn

Stocklytics home · Screener